Trial Profile

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary) ; Teclistamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Acronyms MajesTEC-2
Sponsors Janssen Research & Development

Most Recent Events

06 Jul 2026 Actual primary completion date changed from 13 Oct 2025 to 3 Oct 2025.
05 Jun 2026 Primary completion date changed to 13 Oct 2025.
09 Feb 2026 Planned End Date changed from 5 Oct 2027 to 13 Oct 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com